Last reviewed · How we verify
Dupilumab Only Product
At a glance
| Generic name | Dupilumab Only Product |
|---|---|
| Also known as | dupixent |
| Sponsor | Eric Simpson |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases (PHASE1, PHASE2)
- A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants. (PHASE1)
- Dupilumab Therapy in Nephrotic Syndrome in Children (PHASE2)
- Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus (PHASE2)
- Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults (PHASE1)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Viral Infection in Asthma (VIA) Study (PHASE4)
- Dupilumab for Prevention of Recurrence of CRSwNP After ESS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab Only Product CI brief — competitive landscape report
- Dupilumab Only Product updates RSS · CI watch RSS
- Eric Simpson portfolio CI